Report Phase 3 clinical trial data
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2021
- Due
- 31 Jul 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“PH 3 Data Read (Jun-July)”
What we found
Evidence strength A What the grades mean
The company did not report Phase 3 data by the July 2021 deadline; subsequent filings indicate the Phase 3 component remained dependent on Phase 2 outcomes, which were still ongoing in 2022.
-
A NeuroBo Pharmaceuticals, Inc. 10-K filed 2022-03-31
“ANA001 is currently being studied in a 60-subject Phase 2 clinical trial conducted in the United States, with a Phase 3 component dependent on the outcome of the Phase 2 data.” ✓ confirmed on the page
-
A NeuroBo Pharmaceuticals, Inc. 10-Q filed 2022-08-12
“Enrollment in the Phase 2 clinical trial for ANA001 was closed in July 2022 and a Phase 3 component is planned dependent on the outcome of the Phase 2 data” ✓ confirmed on the page
Market reaction: the shares moved -2.5% against the S&P 500 over the three sessions around the disclosure (30 Mar 2022 to 4 Apr 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 clinical trial data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you NeuroBo Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MTVA-021390 · Corrections policy